mRNA Vaccine Slows Melanoma Recurrence
10.1158/2159-8290.cd-nb2023-0028 · doi-reference
10.1200/jco.2012.44.3762
10.1200/jco.2012.44.3762 · doi-reference
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
10.1016/s1470-2045(13)70510-2 · doi-reference
BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma
10.1586/erv.11.132 · doi-reference
PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine
10.1158/1078-0432.ccr-10-3126 · doi-reference
CIMAvax-EGF: a new therapeutic vaccine for advanced non-small cell lung cancer patients
10.3389/fimmu.2017.00269 · doi-reference
Oncolytic virus-mediated reversal of impaired tumor antigen presentation
10.3389/fonc.2014.00077 · doi-reference
10.1038/nrurol.2018.10
10.1038/nrurol.2018.10 · doi-reference
10.1038/cdd.2014.96
10.1038/cdd.2014.96 · doi-reference
Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine
10.1007/s00262-012-1258-9 · doi-reference
10.1038/emboj.2012.2
10.1038/emboj.2012.2 · doi-reference
Chitosan plus compound 48/80: formulation and preliminary evaluation as a hepatitis b vaccine adjuvant
10.3390/pharmaceutics11020072 · doi-reference
A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients
10.1186/s40425-019-0625-x · doi-reference
10.1016/j.vaccine.2008.06.099
10.1016/j.vaccine.2008.06.099 · doi-reference
10.1126/science.abb4255
10.1126/science.abb4255 · doi-reference
10.1016/j.coi.2011.08.003
10.1016/j.coi.2011.08.003 · doi-reference
10.3390/cancers14215270
10.3390/cancers14215270 · doi-reference
10.1038/ni.2366
10.1038/ni.2366 · doi-reference
10.3390/cancers13020167
10.3390/cancers13020167 · doi-reference
10.1038/s41577-018-0066-7
10.1038/s41577-018-0066-7 · doi-reference
10.1111/febs.14467
10.1111/febs.14467 · doi-reference
Unveiling the Multifaceted Roles of ISG15: From Immunomodulation to Therapeutic Frontiers
10.3390/vaccines12020153 · doi-reference
Detection of immunogenic cell death and its relevance for cancer therapy
10.1038/s41419-020-03221-2 · doi-reference
10.1016/j.immuni.2010.10.002
10.1016/j.immuni.2010.10.002 · doi-reference
10.1016/j.addr.2013.05.013
10.1016/j.addr.2013.05.013 · doi-reference
Novavax COVID-19 Vaccine Booster Authorized
10.1001/jama.2022.20028 · doi-reference
Cancer Vaccines, Adjuvants, and Delivery Systems
10.3389/fimmu.2021.627932 · doi-reference
10.1016/j.jconrel.2023.08.049
10.1016/j.jconrel.2023.08.049 · doi-reference
Updated aluminum pharmacokinetics following infant exposures through diet and vaccination
10.1016/j.vaccine.2011.09.124 · doi-reference
10.1016/j.jconrel.2023.02.015
10.1016/j.jconrel.2023.02.015 · doi-reference
JA: Revisiting IL-2: Biology and therapeutic prospects
10.1126/sciimmunol.aat1482 · doi-reference
10.1038/s41586-020-2537-9
10.1038/s41586-020-2537-9 · doi-reference
Complement as an endogenous adjuvant for dendritic cell-mediated induction of retrovirus-specific CTLs
10.1371/journal.ppat.1000891 · doi-reference
Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas
10.1172/jci151239 · doi-reference
JTC801 Induces pH-dependent death specifically in cancer cells and slows growth of tumors in mice
10.1053/j.gastro.2017.12.004 · doi-reference
10.1080/21645515.2019.1665960
10.1080/21645515.2019.1665960 · doi-reference
10.1016/j.cytogfr.2013.01.005
10.1016/j.cytogfr.2013.01.005 · doi-reference
Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment
10.1016/j.biomaterials.2020.120546 · doi-reference
10.1016/j.biomaterials.2016.06.032
10.1016/j.biomaterials.2016.06.032 · doi-reference
10.1016/j.canlet.2018.08.028
10.1016/j.canlet.2018.08.028 · doi-reference
